Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
I
493280
vs
K
KOSPI 200
Over the past 12 months, IMBiologics Corp has underperformed KOSPI 200, delivering a return of -21% compared to KOSPI 200's +119% growth.
Stocks Performance
493280 vs KOSPI 200
Performance Gap
493280 vs KOSPI 200
Performance By Year
493280 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
IMBiologics Corp
Glance View
Imbiologics Corp. engages in the development of antibody drugs for autoimmune diseases and immuno-oncology. The firm is mainly engaged in the research and development of innovative medicines based on immunomodulatory biological agents. In addition, the company develops differentiated treatments in the fields of autoimmune diseases and immuno-oncology based on technology for producing optimal antibody modalities.